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Abstract 
Vaccination is a cornerstone of influenza prevention, but limited vaccine uptake was a problem 
worldwide during the 2009-2010 pandemic. Community acceptance of a vaccine is a critical 
determinant of its effectiveness, but studies have been confined to high-income countries. We 
conducted a cross-sectional, mixed-method study in urban and rural Pune, India in 2012-2013. Semi-
structured explanatory model interviews were administered to community residents (n=436) to study 
awareness, experience and preference between available vaccines for pandemic influenza. Focus 
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group discussions and in-depth interviews complemented the survey. Awareness of pandemic 
influenza vaccines was low (25%). Some respondents did not consider vaccines relevant for adults, 
but nearly all (94.7%), when asked, believed that a vaccine would prevent swine flu. Reported vaccine 
uptake however was 8.3%. Main themes identified as reasons for uptake were having heard of a 
death from swine flu, health care provider recommendation or affiliation with the health system, 
influence of peers and information from media. Reasons for non-use were low perceived personal 
risk, problems with access and cost, inadequate information and a perceived lack of a government 
mandate endorsing influenza vaccines. A majority indicated a preference for injectable over nasal 
vaccines, especially in remote rural areas. Hesitancy from a lack of confidence in pandemic influenza 
vaccines appears to have been less of an issue than access, complacency and other sociocultural 
considerations. Recent influenza outbreaks in 2015 highlight a need to reconsider policy for routine 
influenza vaccination while paying attention to sociocultural factors and community preferences for 
effective vaccine action.  
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Introduction 
Vaccination is a critical tool for controlling influenza. When faced with a pandemic, swift 
deployment of vaccines is crucial to limiting spread of the disease before the virus acquires increased 
pathogenicity or antiviral resistance.
1
 On 11 June 2009, the World Health Organization (WHO) 
declared a global influenza pandemic caused by a novel influenza A (H1N1) virus.
2
 Efforts were made 
to ensure adequate supply of vaccines. Yet, lower-than-anticipated uptake of the vaccine was a 
notable problem, even among high risk groups.
3-7
 Studies exploring vaccine hesitancy and reasons 
for poor uptake that limit effectiveness of a pandemic response have been largely restricted to high-
income settings.
8-11
 Despite acknowledged cross-cultural differences in public response to pandemic 
influenza and need for country-specific studies,
12,13
 few have been conducted in lower income 
settings. 
A large burden of 2009 H1N1 influenza was borne by low-income countries.
14,15
 India reported 
39,977 cases and 2,113 deaths from H1N1 influenza between May 2009 and August 2010.
16
 These 
numbers, which refer to laboratory-confirmed cases, are likely underestimated. The city of Pune, 
which suffered high morbidity and mortality,
17-19
 is incidentally home to a large vaccine manufacturer, 
Serum Institute of India Ltd. Inactivated influenza vaccine (IIV, injectable administration) and live 
attenuated influenza vaccine (LAIV, nasal administration) were available for public purchase in Pune 
during the 2009 pandemic.
20
 While IIVs alone are licensed for certain groups (children under 2 years, 
persons 50 years and above and pregnant women), both types of vaccines are considered efficacious 
and safe for the larger population.
21-27
 
Demand for vaccines varied widely in India. In some cases, influenza vaccines were eagerly 
sought
28,29
 but at other times there were few takers.
30,31
 This variability highlights the importance of 
understanding community acceptance and facilitators and barriers for vaccine uptake. Although 
nasally administered LAIV is generally considered less invasive than IIV by health professionals, and 
it was available at a lower cost than IIVs in Pune, it is nonetheless a relatively new form of vaccine 
administration in India and questions arise about its community acceptability for influenza vaccination. 
Addressing questions about community preferences for one or other vaccine is likely to contribute to 
our understanding of vaccine hesitancy or confidence in their sociocultural context, which are critical 
determinants of effective influenza vaccine action. 
Acknowledging sociocultural differences and differences in access to health services in urban and 
rural communities, we conducted a mixed-method study in low-resource and middle-income urban 
areas, and in accessible and remote rural areas of Pune, India.
32
 The first part of the study exploring 
community understanding and experience of pandemic influenza has recently been reported.
33
 In this 
paper, we focus on the community-perceived role of vaccines with the objectives of (a) determining 
community awareness and views of pandemic influenza vaccination, (b) analysing experience and 
reasons for vaccination or non-vaccination against H1N1 influenza during the 2009 pandemic and (c) 
clarifying community perceptions and preferences for either injectable or nasal influenza vaccines. A 
review of experience and community perceptions of vaccines for pandemic influenza in India provides 
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a unique opportunity to inform planning for other immunization initiatives and recurring influenza 
outbreaks. 
Results 
Sample characteristics 
Focus groups discussions (FGDs) were conducted in July 2012, semi-structured interviews (SSIs) 
from August to December 2012 and in-depth interviews (IDIs) between March and April 2013. Five 
FGDs (each with 5-6 participants), 12 IDIs and 436 SSIs have been analysed (Table 1). Among SSI 
respondents, those from the urban sites had received more education and had higher incomes; more 
details have been reported elsewhere.
33
 
Awareness of vaccines: in general and for pandemic influenza 
Awareness of the role of vaccines in preventing illnesses was noted: “A vaccine is given for 
prevention of an illness which we may get in the future” (man, rural FGD). However, confusion about 
the preventive versus curative aspect of vaccines was also noted among some respondents. For 
example, a 65-year-old rural woman stated: “[By taking the vaccine] the illness could have been 
prevented and she would have got cured” (SSI). 
Vaccines were sometimes distinguished by their mode of delivery. “It is an injection and it has 
medicine in it” (27 years, rural woman, IDI). They were also explained by terms appropriate for other 
vaccines that respondents were familiar with. A woman during a FGD in a rural area explained her 
idea of a vaccine by stating: “We call it dose - triple, polio”. 
Some respondents thought vaccines were relevant only for children and expressed concern about 
their use for adults. “All children are vaccinated. But adults are not vaccinated. I think the vaccine is 
effective for ages 1 to 5. We don‟t have experience with vaccines being effective at later ages” (man, 
rural FGD). 
Over a quarter of respondents said they were aware of a vaccine administered as a nasal spray for 
swine flu (Table 2). There was a significant difference in awareness based on age group (the younger 
age group of 18-45 years had higher awareness than the older age group of 46-65 years) and area of 
residence, with highest awareness in the urban middle-income area (47.1%) and lowest in the rural 
remote area (8.3%). Slightly fewer respondents (23.4%) reported awareness of an injectable vaccine 
to prevent swine flu. 
When respondents were asked whether they had received advice regarding vaccines for swine flu 
from their health care providers, 15.8% of respondents reported that they had (Table 2). A larger 
percentage of these respondents were from the younger age group and from the urban sites. 
Views on benefits and problems with pandemic influenza vaccines 
Respondents were asked whether they thought a vaccine could have prevented swine flu. Most 
(94.7%) said yes, and significantly more who said yes were from the younger age group (97.3%) 
compared to the older age group (92.0%, p=0.017). 
An analysis of narratives indicated confidence and trust in vaccines by a large percentage of 
respondents. A 47-year-old man who was confident of the benefits of a pandemic influenza vaccine 
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stated: “[If he had taken the vaccine] he would have been protected. Swine flu can happen only to 
those who have not taken the vaccine” (rural SSI). A few raised concerns about the efficacy of 
pandemic influenza vaccines, while maintaining their support of vaccines in general. For example, an 
urban woman said: 
Getting vaccinated is definitely a good thing but I am not sure whether this vaccine is a proven 
one like other vaccines. I knew 100 percent about the vaccines that were given in early times 
but is there any data available for this new vaccine which proves that those who have taken it 
have not got swine flu? If someone asks me to take it, I won‟t deny. I would believe in it and 
would go for it (45 years, SSI). 
Some who thought reported vaccines were helpful nevertheless had a fatalistic attitude towards 
the illness that did not preclude the vaccine. A 57-year-old urban woman explained: “The illness will 
happen anyhow if it has to happen but there is no harm in taking the vaccine” (SSI). 
Others, however, suggested that destiny made any precaution including vaccines irrelevant: “It will 
happen if it is destined to happen even if she maintains cleanliness or takes any other precaution” (56 
yr, woman, rural SSI). Very few distrusted the vaccine itself or had serious safety concerns. 
Respondents were also specifically asked whether they knew of any problems with either the nasal 
or injectable pandemic influenza vaccines. Almost half (48.2%) said that nasal vaccines did not cause 
any problems and a majority (56.7%) said the same about injectable vaccines. Men were more likely 
than women to say there was no problem with pandemic influenza vaccines, and that perception was 
applicable to both nasal (57.7% men, 38.9% women, p<0.001) and injectable (65.1% men, 48.4% 
women, p<0.001) vaccines. A third of respondents were unable to say whether nasal or injectable 
vaccines caused any problems. The main anticipated problems for the nasal vaccine were discomfort 
or irritation in the nose and throat (12.8%) and runny nose or sneezing (4.4%). For injectable 
vaccines, identified problems included pain or swelling (8.9%) and fever or chills (3.7%). Only one 
person anticipated a serious adverse effect of the vaccines, and this person who lived in the urban 
low-resource area, said death might result from receiving the vaccine. 
Experience with pandemic influenza vaccines 
Of the 436 SSI respondents, 8.3% reported having personally received a pandemic influenza 
vaccine and 10.6% said someone else in their household had taken it (Table 2). The urban middle-
income area had the highest proportion of vaccine acceptors, while the remote rural area had the 
lowest proportion. The more accessible rural area had more vaccine acceptors than the low-resource 
urban area. 
Reasons for vaccine use 
Narratives of those who had indicated household experience with the pandemic influenza vaccine 
(either personal use or someone else in the household who received it), were analysed to identify key 
reasons for vaccine uptake. Salience, social and medical influences, and the influence of media were 
discussed. 
Salience of pandemic influenza: exposure to serious a swine flu-related illness or death 
D
ow
nl
oa
de
d 
by
 [H
arv
ard
 L
ibr
ary
], 
[M
itc
he
ll G
. W
eis
s] 
at 
15
:42
 25
 Ju
ne
 20
15
 
 6 
 
The decision to vaccinate for pandemic influenza was strongly motivated by having seen someone 
suffer from the illness or having heard of a death from swine flu. A 31-year-old urban woman 
explained: “My sister's colleague's son suffered from it. He is alive but his friend who used to play with 
him died. When I heard about this, I became seriously concerned and I vaccinated my son” (IDI). A 
rural woman who had taken the vaccine explained that fear drove her to action after a pregnant 
woman in her village had died from swine flu: 
After one lady died and my son had swine flu, everyone was scared. They felt that if this 
continues, everyone in the village would die. Nobody from the government came here so 
members of a youth group called a private doctor so that our villagers would get the vaccine 
(45 years, IDI). 
She also recounted her experience at the hospital while caring for her son with suspected swine flu 
illness as follows: 
I observed that when a person was admitted with breathlessness, that person would die 
immediately. Yes, I have seen such people in Sassoon hospital. Once the person was taken 
inside the ICU, only their dead body would come out. People were therefore preoccupied with 
fear. 
Social influence 
Conduct of free vaccination camps in one‟s neighbourhood or at school were reported as reasons 
for taking the vaccine. In a village where a vaccination camp was conducted, peer effects seemed to 
motivate vaccine uptake. A 45-year-old rural woman explained: “Everyone in the village took the 
vaccine, so I also took it to prevent anything before it happens” (IDI). 
Medical influence 
Recommendation by a health care provider in the family influenced vaccine uptake for some. An 
urban woman explained her reasons for taking the vaccine as follows: “The epidemic was at a peak 
and my nephew is a doctor. He was giving the vaccine to his friends and relatives. He is our close 
relative and we trust that he will not cheat us.” (65 yr, IDI). Other connections with the health system, 
such as working in a hospital, also influenced vaccine uptake. An urban woman said: “I took the 
vaccine. I work as a security guard in a private hospital. It was given free of cost in our hospital. (33 
yr, SSI) 
Influence of media 
Information from media reports was an important factor for people who actively sought the vaccine. 
An urban man explained: “When I read the newspapers, I understood its seriousness, and thought 
that I should not waste time and therefore took the vaccine immediately” (64 yr, IDI). But they 
acknowledged the importance of information on where they could get vaccinated from pamphlets from 
provided by the Pune Municipal Corporation or volunteers who came door-to-door. However, it was 
often noted that while the media was a useful source of information, doctors were consulted before 
taking the vaccine: “The media was discussing availability of vaccines. But we didn‟t rely on the 
media, we always consulted doctors” (37 yr, urban IDI). 
Reasons for vaccine non-use 
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When SSI-respondents were asked why they or anyone in their household had not taken the 
vaccine for swine flu, several common reasons were reported (Table 3). 
Low perceived risk 
A majority (55.0%) indicated low risk attributed to influenza or a sense that they were not personally at 
risk. Men were more likely to say that than women. Common accounts referred to the following points: 
First, if there were no cases of swine flu in the respondent‟s neighbourhood, a vaccine seemed 
unnecessary. In the urban areas, this was explained largely in terms of a lack of observable 
symptomatic cases in the neighbourhood: “If somebody from our housing society gets swine flu, then I 
would go and take it. If there are no such cases around, then why should I take the vaccine?” (57 yr, 
urban woman, IDI). Similar explanations were noted in the rural area, but complemented by 
assertions that swine flu was an urban problem that had not reached rural areas. A readily apparent 
epidemic was required to convince people of the salience of the illness. A man articulated this 
sentiment metaphorically: “Suppose, there is a violent and rampant dog biting everyone, only then will 
a concerted effort be made to kill him. Similarly, in the absence of an epidemic, people will not take 
the vaccine.” (rural FGD). Second, the respondent‟s idea that personal strength and good health 
would confer protection from illness was mainly reported by men. For example: “We don‟t need the 
vaccine. I am physically fit, I am a sportsman; mostly we won‟t get it” (26 yr, rural man, SSI). Women 
frequently referred to reduced chances of contracting the illness because they stayed at home: “Men 
are exposed to the outside, but we are always at home, hence we do not consider ourselves at risk of 
catching the illness” (27 yr, urban woman, SSI). Faith in God as a basis for perceived protection was 
also mentioned. “We believe in our god. We believed that we won‟t ever get swine flu, and we 
haven‟t” (35 yr, urban man, SSI). Lastly a low priority for prevention, due to confidence in effective 
treatment was also noted: “When there are illnesses in the rural areas, then a cure is made available 
there. Nobody takes prior care” (25 yr, rural woman, SSI). 
Other preventive measures make vaccines unnecessary 
Adequacy of other preventive measures apart from vaccines was reported by 15.8% as a reason 
for not taking the vaccine, more so by urban than rural respondents (p<0.001). Widely mentioned 
alternative preventive measures included the use of face masks (often referred to tying a 
handkerchief around the nose and mouth), maintaining personal hygiene, keeping surroundings clean 
and avoiding crowds. Some also referred to the use of preventive drugs, specifically mentioning 
antiviral drugs: “We did not feel the need to take it since there were other things like masks and 
Tamiflu” (24 yr, urban man, SSI). A few also mentioned herbal preventive measures: “We used 
prevention measures – wearing a mask, using camphor and nilgiri [eucalyptus] oil. So, we did not feel 
the need to take the vaccine” (33 yr, urban man, SSI).There was also infrequent mention of chanting 
of prayer and ritual purification („agnihotra‟). 
Lack of information about the vaccine 
Some (11.7%) respondents were unaware of the existence of a vaccine against pandemic 
influenza. The largest proportion of such respondents was from the rural remote area, followed by the 
urban low-resource area and the lowest proportion was from the urban middle-income area. A rural 
woman explained: “Two years ago when there was an outbreak of swine flu, we were not even aware 
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that there was a vaccine for swine flu” (28 yr, SSI). This reason was often mentioned in combination 
with problematic access, i.e., not knowing where to obtain the vaccine. 
Problems with access and cost 
Difficulties relating to obtaining the pandemic influenza vaccine were noted by 14.7% of SSI 
respondents, with significantly more from rural than urban areas. The most frequently mentioned 
problem was that the vaccine was not delivered to the respondents‟ neighbourhoods. Rural 
respondents expected that important interventions would be delivered by government health workers. 
They were not sure how or where to get a vaccine if it was not brought to their villages. A rural woman 
explained why she did not take the vaccine as follows: “The most important reason was that the 
vaccine did not come here, and we do not know where to go and get it” (35 yr, SSI). Another problem 
for accessing the vaccine was not having a clinic nearby. A few respondents also noted the vaccine 
was available only for children and not adults. A 22-year-old woman who also drew a parallel with 
polio vaccine campaigns said: “It hasn‟t come here yet. For children up to 5 years they come to give 
the polio vaccine. For swine flu also they came here to vaccinate children but not adults” (urban SSI). 
A few noted unavailability of the vaccine during the pandemic as a reason: “There was no vaccine 
at that time when the illness more widespread. The vaccine came later” (46 yr, urban man, SSI). Nine 
respondents indicated that they wished to take the vaccine but were unable to do so as it was out of 
stock due to high demand. Seven respondents said they had no time to spare to go and get the 
vaccine. 
Financial constraints as a reason for not taking the vaccine were reported by 5%. Among these 
respondents, many stated that they would have taken it if the government had provided the vaccine 
for free or at a discounted price. 
Insufficient indication of vaccine priority 
Some respondents explained that health care providers, the government or people they knew had 
not clearly indicated the importance of vaccination or encouraged it. An urban woman stated: “No one 
forced me or urged me to take the vaccine. No one asked me to come along to take it. Had someone 
urged me, I would have taken it. Neither the doctor nor family members urged me” (57 yr, SSI). The 
lack of a mandate by the government for pandemic influenza vaccination was also indicated as a 
reason by some: “The government did not carry out any promotional activities and there was no 
compulsion by the government to take the vaccine” (62 years, rural man, RM223). 
Other concerns 
Four respondents expressed concerns about vaccine effectiveness; four indicated a general 
avoidance of medication, and one mentioned a fear of adverse reactions. No one indicated other 
concerns about the vaccine or type of administration as a reason for not having taken the vaccine. 
Preference for injectable or nasal vaccine 
Data indicate a strong preference for injectable over nasal vaccines. Twice as many respondents 
reported preference for an injectable vaccine and considered it safer (Table 4). Among those who 
considered a nasal vaccine safer, more were from the urban middle-income area, followed by the 
accessible rural area, the urban low resource and finally the rural remote area. When respondents 
were asked which vaccine they considered more powerful, 44.3% opted for the injectable and 32.6% 
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for the nasal. Those who reported no specific preference for either vaccine referred to (a) a sense of 
urgency in obtaining whichever vaccine was available, (b) prioritizing convenience and getting the 
vaccine that was most easily available, (c) the need to follow a doctor‟s advice and to not question 
what the doctor recommends, or (d) lack of their own opinion due to lack of experience with this new 
illness. Main themes that emerged from the narrative data of SSIs and IDIs in explaining preference 
for either the injectable vaccine or the nasal vaccine are described in the next section, with narratives 
quoted in Table 5. 
Reasons for preferring an injectable vaccine 
Injectable vaccine considered more powerful than nasal one 
A commonly cited reason for preferring an injectable vaccine was that the vaccine would be 
directly absorbed in the blood and thus more effective. This account was frequently described in 
contrast to nasal vaccines, which were perceived as ineffective because they were likely to be 
expelled easily while breathing, and fail to reach all parts of the body. Ideas that injections work faster 
and had a longer duration of protection than nasal vaccines were also suggested to explain 
preferences. A few respondents said pain from an injection was an indication of its power. 
Fear of side effects from a nasal vaccine 
Many referred to fear of side effects from the nasal vaccine as a reason they preferred the 
injectable one. The numerous perceived side effects from nasal vaccines that were mentioned 
included irritation in the throat, burning sensation in the eyes, sneezing, pain in the nose, vomiting, 
breathlessness, a tingling sensation or numbness in the head, a bitter taste in the mouth and general 
discomfort. Others, who were unable to identify specific side effects, referred merely to being unable 
to tolerate a nasal vaccine. 
Experience and familiarity with injections 
Past experience and familiarity with injections compared to a relatively new nasal vaccine was 
another major reason for preferring injectable vaccines. Many respondents had an implicit trust in 
injections. Conversely, absence of familiarity and fear of relatively unknown nasal vaccines were 
frequently reported as reasons for preferring injectable vaccines. 
Favourable attitude towards injections and preference regardless of perceived efficacy 
A favourable attitude towards injections in general was observed and while this is linked to the 
theme of perceiving an injectable vaccine as powerful, it was qualitatively distinct in that injections 
were considered a panacea for all illnesses and the best form of administering any drug. A 65-year-
old man explained: “Now suppose you want to take a vitamin supplement. You get it in the form of 
tablets, injections and liquid. But, of these, the injection spreads throughout the body” (urban SSI). On 
a similar note, a rural woman said: “Weakness reduces on administering the injection...one feels 
better after taking them” (47 yr, SSI). A few respondents reported preference for an injectable 
vaccine, despite their belief that nasal vaccines were more effective. 
Reasons for preferring a nasal vaccine 
Nasal vaccine considered more powerful than an injectable one 
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Those who preferred a nasal vaccine believed in the superior power of nasal vaccines to reach all 
parts of the body through one‟s breathing. Immediacy of effect was also noted. Administration through 
the nose was a perceived advantage because that was also the point of entry for germs causing 
swine flu. Some referred to physical sensations after receiving the vaccine as an indication of the 
vaccine doing its job. This was considered a desirable side effect of nasal vaccines. On a similar note, 
the idea that the nasal vaccine can spread to the brain was lauded as a measure of its powerfulness 
by a few who explained their preference for nasal vaccines. However, the same point was regarded 
as an adverse effect for those shunning the nasal vaccine. 
Safety concerns for injectable vaccines and fear of needles 
Some preferred a nasal vaccine due to concern about the safety of needles, which might have 
been previously used. This concern was noted only by urban respondents. Pain or swelling from an 
injection was a reason for preferring a nasal vaccine, but stated only by a few. 
Discussion 
Findings suggest trust in vaccines in general and for pandemic influenza vaccines in rural and 
urban communities of Pune district. A clear understanding of the rationale, however, of vaccines 
designed primarily for healthy individuals to prevent disease was lacking. Many respondents 
suggested no need for a pandemic influenza in the absence of fever or symptoms. A news report in 
Pune during the pandemic exemplifies the misconception. A young man suffering from symptoms of 
influenza who purchased a LAIV from a pharmacy and had it administered in a hospital subsequently 
died.
34
 Some respondents thought vaccines were only relevant for children and irrelevant for adults. 
Data from rural Pune during and after the pandemic suggest that incidence of hospitalized H1N1 
influenza was highest among 5-29 year olds.
35
 Both the epidemiology and our findings suggest the 
need for promoting awareness of the public and health care providers of the value of vaccination for 
adults, and awareness of contraindications and precautions for vaccination.
21
 
Awareness of the role of vaccines in preventing pandemic influenza was relatively low at 25%. A 
study in Bareilly, Uttar Pradesh, during the pandemic reported awareness of vaccines against swine 
flu among 47% of studied school students.
36
 Notwithstanding low awareness in our study, most 
respondents, when asked about pandemic influenza vaccines, reported them as potentially helpful in 
preventing swine flu. Problems or side effects of the vaccine were mostly localized and seldom 
reported as a barrier to vaccine uptake. This is unlike studies from other countries
9,10,37
 or studies in 
India among health care workers
38,39
 where perceived side effects from the vaccine were reported as 
a deterrent to influenza vaccination intention. Although for the majority a vaccine with fewer side 
effects was preferred, the finding that for some, a localized reaction or physical sensation after 
vaccination was an indicator of vaccine efficacy and hence desirable, was unique to our study. It is 
also interesting to note that some considered an injection as less invasive than a nasal vaccine. It was 
said that “one does not feel anything or one feels good” after taking an injection, while nasal vaccines 
were perceived to have many more potential side effects. Fear of injections was noted by just a few 
and concerns about re-use of needles for injectable vaccines were reported largely in the urban 
middle-income area. 
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Study findings show a majority of the community preferred for injectable compared to nasal 
vaccines. Excessive, often unnecessary use of injections has been documented in India
40
 and in other 
parts of Asia.
41,42
 The placebo effect offered by injections has provided an argument for widely using 
injections in India and is often demanded by patients. A study by Greenhalgh
43
 in 1987 questioned 
blind faith in injections, and our findings suggest that these perceptions continue to hold true. While 
inactivated injectable vaccines are required for special groups, live-attenuated vaccines offer practical 
advantages for control of pandemics the general population in a country as highly populated as India. 
They are easier to administer and easier to produce larger quantities at lower cost.
20
 Our findings 
suggest lack of community familiarity, rather than confidence, with this relatively new form of vaccine 
administration. Respondents from the urban middle-income area were more aware of nasal vaccines 
and more likely to consider them as the safer vaccine. Thus, gaining public support is not likely to 
pose a problem if implemented with effective communication and engagement. The success of the 
oral polio vaccine campaign in India demonstrates good prospects for widespread public acceptance 
of this new form of vaccine administration. Paterson and Larson recommend public engagement by 
building trust and learning about public concerns to be addressed,
44
 and by communicating openly, 
honestly and proactively with the public and other stakeholders.
45
 Our study identified the following 
key concepts that study communities attributed to the vaccine they preferred, either nasal or 
injectable, that should be well-understood and convincing, namely, the: ability of the vaccine to spread 
to all parts of the body and immediacy of effect. Properties of the vaccine itself – whether it was live 
attenuated or inactivated – were never mentioned spontaneously or questioned by any respondents. 
It is likely not a distinction of practical significance for respondents. 
Findings suggest a blurring of urban-rural distinctions in the rapidly urbanizing Pune district. 
Notwithstanding highest awareness and vaccine uptake in the urban middle-income area, awareness 
of nasal influenza vaccines, belief in safety of nasal compared to injectable vaccines and use of 
pandemic influenza vaccine were reported by more respondents from the accessible rural area than 
from the low-resource urban area. The urban-rural dichotomy may be superseded by other factors 
with regard to vaccine policy and planning in such rapidly urbanizing settings
46
 where people in 
accessible rural areas may have higher incomes and better access to information than persons in 
urban slums. More men than women had confidence in the power of nasal vaccines and anticipated 
no problems with pandemic influenza vaccines; yet they were also more likely to perceive a low risk 
for themselves in getting swine flu. Age-specific differences in awareness of nasal vaccines and in the 
ability of vaccines to prevent influenza indicate a need to inform older segments of the population. 
The reported swine flu vaccine uptake rate was 8.3% in our study, but limitations in production and 
access may help explain the low figure. Vaccines were only available many months into the 
pandemic.
47,48
 There was no state-wide initiative for mass vaccination in Maharashtra although the 
Pune Municipal Corporation provided vaccines without charge to health care workers towards the end 
of the pandemic.
49
 Furthermore, some hospitals and groups conducted their own vaccination camps. 
The nature of vaccine uptake varied. It was passive acceptance for some when the vaccine was 
made available in their neighbourhood, and active demand for others who made an effort to go and 
get it themselves.
50
 The Indian Medical Association and Indian Academy of Pediatrics officially 
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recommended the pandemic influenza vaccine,
51
 but individuals had to purchase it privately. The 
public health dissemination strategy for communication information from the state about vaccine 
recommendations was unclear. The media played a major role in public communication, but this did 
not appear to be state-directed. Furthermore, the response to the pandemic by the state government 
seemed to focus on treatment with antivirals rather than preventive measures. 
The influence of salience of the illness from personal experience with cases or deaths in the 
neighbourhood was a powerful motivator for vaccine uptake in our study. A similar finding was 
reported by SteelFisher et al
10
 in a study done in the United States of America (USA). A study using 
self-administered questionnaires among health care workers in Pune noted “self-protection against 
illness” as the main reason for accepting H1N1 influenza vaccination.
52
 Inasmuch as we surveyed 
community residents, we were able to identify additional practical reasons for vaccine acceptance, 
such as health system affiliation, health care provider recommendation, influence of peers and media 
impact. 
A majority considered the illness as very serious or serious.
33
 Nevertheless, some who 
acknowledged the seriousness did not consider themselves to be personally at risk. According to the 
health belief model, without perceived personal risk, considering an illness as serious may not 
translate into protective behaviour.
53
 Gendered explanations of perceived personal risk were notable. 
Men regarded themselves as too strong to catch the illness (a „man of steel‟ perception) and women 
considered themselves at reduced risk from being homebound. The above findings on low risk 
perception for oneself along with the belief that it was an urban but not a rural problem, suggest an 
optimism bias
54
 where people consider themselves unlikely to catch an illness that they consider 
serious for others. 
Access was a barrier because of community expectations that a vaccine, if relevant, would be 
delivered through a campaign in one‟s neighbourhood. Such expectations may be a result of 
community experience with the vertical polio vaccination programme in India. A clear message from 
the government endorsing pandemic influenza vaccines, which the community indicated was lacking 
in the 2009 influenza pandemic, may promote vaccine uptake. Education of health care providers 
needs to ensure they make appropriate recommendations of vaccines. With respect to the SAGE 
Working Group framework of vaccine hesitancy, 
55
 our findings indicate that lack of confidence in 
pandemic influenza vaccines may not be a serious problem for uptake, but convenient access, 
complacency, and other sociocultural considerations take precedence. 
Dissemination activities 
The research team had planned community dissemination activities from the outset. After 
completing the field research and initial analysis, insights and information gained from the study were 
presented in meetings with urban and rural study communities. Urban and rural community members 
participated in meetings at their respective study sites, and a dissemination workshop was held in 
Pune for various levels of policy makers in November 2014. Officials from the central government, 
municipality and subdistricts participated. A brochure for community residents and a policy brief for 
policy makers was prepared, distributed and discussed at these events. 
Strengths 
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The need and value in engaging the public in vaccination initiatives has been well-
established.
44,56,57
 Recently documented challenges of introducing new vaccines in India,
58-60
 highlight 
the importance of studies that focus on understanding community perceptions, underlying issues and 
contextual influences that may influence vaccine acceptance. To the best of our knowledge, our study 
is the first to explore community views, preferences and uptake of pandemic influenza vaccination in 
India. One other study considered community perceptions of influenza during the pandemic in India,
61
 
but was limited in its study of views of vaccines. Multiple methods used in our study – focus group 
discussions, semi-structured interviews and in-depth interviews – made triangulation of results 
possible. Quantitative survey findings indicated not only what the issues are but the relative frequency 
of particular perceptions and priorities; qualitative narrative data from SSIs helped explain what these 
ideas meant and IDIs enriched qualitative detail. 
Limitations 
The study was designed to provide relevant information and guidance in a local cultural context. 
Generalizations for other parts of the country must therefore be made with caution. The survey was 
cross-sectional, and community views and perceptions are subject to change over time and in 
response to other social or policy changes. Vaccine uptake was documented through self-report and 
the idea of a preventive vaccine was not clearly appreciated by some respondents. We did not 
confirm whether respondents who said they had taken a pandemic influenza vaccine actually did. By 
assuring participants that there were no right or wrong answers, assuring confidentiality, and 
presenting interviewers as independent researchers we attempted to minimize response bias. There 
is a possibility of recall bias since data collection for this study began two years after the officially 
declared end of the pandemic in 2010.
62
 Persisting media coverage of swine flu and consideration of 
vaccines, however, even during our data collection ensured a public memory of the illness and its 
control. 
Conclusion 
This study has elucidated cultural perceptions and ideas about the value of vaccines for pandemic 
influenza among urban and rural communities of Pune, India, which have practical implications for 
pandemic influenza control. In the 2009-2010 influenza pandemic, a community mass vaccination 
was not conducted in Pune. People had to pay the full price for a vaccine and display considerable 
initiative to obtain it. Our study examined reasons for use and non-use of influenza vaccines in this 
context largely through qualitative approaches. Policy implications from study findings highlight good 
prospects for use of influenza vaccines for pandemic control given community trust in vaccines. If a 
mass vaccination were to be planned for influenza control in the future, attention to the following 
recommendations may help enhance vaccination coverage: (1) Increase community awareness about 
influenza vaccines, (2) Emphasise their relevance for adults, (3) Emphasise risk for urban and rural 
communities, men and women, (4) Promote vaccination through health care providers, community 
leaders and government endorsement, (5) Deliver the vaccine right to communities at an affordable 
cost, (6) If nasal vaccines are considered, they need to be explained through effective communication 
addressing community concerns, (6) Plans should consider setting-specific differences within urban 
and rural areas. Questions about use of vaccines for control of seasonal influenza among high-risk 
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groups and the general population also require further consideration and study. This is especially 
relevant in the light of recent large outbreaks of H1N1 influenza,
63,64
 which is now considered a 
seasonal strain. Lack of priority for routine use of influenza vaccines at present
65
 despite production 
capacity for influenza vaccines in India, suggests that reconsideration of policy, and sociocultural 
community studies are needed to guide further development of vaccine policy for effective action. 
Methods 
Study area 
This study was conducted in Pune district, a focus of the 2009-2010 (H1N1) influenza pandemic in 
India. The district had a large number of cases and recorded the country‟s first death from H1N1 
influenza in 2009. Study sites were selected in urban and rural areas. Two urban sites were low-
resource densely populated (slum) settlements in Sangamwadi and middle-income neighbourhoods 
of Erandawane in Pune city. The rural sites comprised villages in Maval subdistrict that were more 
accessible to Pune city due to their location along a highway and more remote villages in Velhe 
subdistrict that were relatively difficult to access. Further details on setting are reported elsewhere.
32,33
 
Study design 
A mixed-methods, cross-sectional and community-based study was conducted in urban and rural 
areas of Pune district. The present analysis focuses on community awareness, preference and use of 
vaccines to prevent pandemic influenza, and primarily had a qualitative focus. We employed multiple 
methods including focus group discussions, cultural epidemiological semi-structured interviews 
integrating qualitative and quantitative data, and qualitative in-depth interviews. Formative focus 
group discussions (FGDs) provided insight on the setting and guided development of questions and 
categories of semi-structured interviews (SSIs). SSIs were developed based on the explanatory 
model interview catalogue (EMIC)
66
 framework for cultural epidemiology
67
 to obtain representative 
distributions of perceptions of pandemic influenza and the role of vaccines. Additional in-depth 
interviews (IDIs) were conducted to gain a deeper understanding of experiences and motivations of 
those who took the pandemic H1N1 influenza vaccine, and the views, potential barriers or hesitation 
among those who did not do so. 
Instruments and respondent selection 
Inclusion criteria for FGDs, SSIs and IDIs were resident adults (18-65 years) in the community with 
conversational fluency in Marathi and ability to mentally and physically withstand the interview or 
discussion. 
Respondents for SSIs were randomly selected from voters‟ lists for each of the study areas.
33
 
Voters‟ lists, which were the most comprehensive of available records, were obtained for each of the 
study areas. One hundred and ten households were randomly selected for each area using a random 
number generator. To avoid selection bias inherent to use of voters‟ lists, selected households were 
located but not interviewed. The neighbouring household to the right was approached for interview 
instead. If no member of the household satisfied the inclusion criteria or if there were no willing 
participants, the adjacent household to the right was approached, until a suitable respondent was 
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found. An equal balance of men and women and younger (18-45 years) and older (46-65 years) age 
groups was maintained. Questions related to awareness, preferences, uptake of pandemic influenza 
vaccines and barriers to vaccine use were considered for this report. Quantifiable coded responses 
were collected and any quantitative data presented in this report came from the analysis of SSIs. 
Specific questions that the coded responses correspond to have been included as footnotes to the 
tables. Narratives in response to open questions in the SSIs complement the quantitative data. IDIs 
were conducted with a purposively-selected subsample from the SSIs. The IDIs provided accounts 
enriched by context and reasons for vaccine use or non-use. FGDs were conducted in urban and 
rural study areas based on a convenience sample recruited by community leaders or community 
health volunteers. The FGD agenda covered similar broad topics on ideas about vaccines including 
perceived benefits, problems and use of pandemic influenza vaccines. 
We designed instruments for all three methods during several workshops based on a literature 
review and previous work on vaccine acceptance.
68-70
 Instruments were revised based on feedback 
from other experts and public health professionals. Instruments were pilot tested and further revised 
after translation into Marathi. 
Data collection 
Research assistants conducting the SSIs had Masters-level qualifications in social sciences, were 
native Marathi speakers and received training in interview skills and data management. They worked 
in pairs with one person conducting the interview and the other maintaining data records. SSIs lasted 
for 45 minutes on average. Data sheets were checked for accuracy and discrepancies resolved while 
in the field. 
FGDs and IDIs were conducted by one of two bi-lingual senior researchers with doctoral and 
masters-level degrees in social sciences, accompanied by a note taker. The average duration of 
FGDs was 1 hour and IDIs was 40 minutes. Facilitators and note takers discussed impressions and 
compared notes after each FGD and IDI. 
Interviewer and respondent characteristics were matched where possible. For example, a female 
facilitator conducted focus groups with women. Researchers did not have a prior relationship with 
study participants. All interviews and discussion were conducted in Marathi. FGDs, SSIs and IDIs 
were audio recorded with participants‟ consent. 
Data management and approach to analysis 
Qualitative analysis 
Narrative data from SSIs were first entered in a word processor in Marathi and then translated into 
English. Supervisors regularly checked transcriptions and translations for quality. FGD and IDI 
transcripts were translated into English and entered in a word processor on an ongoing basis while 
constantly monitoring data quality with reference to study objectives. 
FGDs, narrative data from SSIs and IDI data were imported into MAXQDA v.11 (VERBI Software, 
Germany) for data management and analysis. Analysis was rooted in the objectives of this paper. 
Thematic coding was done using a deductive approach for first-level coding. Inductive coding was 
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used for secondary and tertiary level codes. Qualitative data collected from the three different 
methods were regarded as complementary in this analytic process of triangulation. 
Quantitative analysis 
Quantitative data from SSIs were entered by the interview team into Epi Info v. 3.5.3 (CDC, USA). 
For double-entry verification, a second entry of quantitative data was done independently by a 
member of another team. Questions that required affirmation or negation were coded on a four point 
Likert scale, ranging from a clear yes or no (values of 3 or 0), to a qualified yes or no (values of 2 or 1) 
for responses. Variables with few qualified responses were dichotomised for analysis. To assess the 
influence of gender, area of residence and age on views and vaccine uptake, systematic comparisons 
were analysed for age group, sex and study area. Significant differences at the 0.05 level have been 
presented in this paper, using Fisher‟s exact test to compare proportions across different groups. 
Quantitative variables were also imported into MAXQDA to review narratives of interest based on 
quantitative associations, thus facilitating integrated analysis of quantitative and qualitative data. Data 
analysis was done with STATA v. 12.1 (StataCorp, USA) and SAS v. 9.3 (SAS Institute Inc., USA). 
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Table 1. Summary of sample characteristics 
  Number of participants 
 
Focus group 
discussion 
(FGD)a, n=28 
Semi-
structured 
interview (SSI), 
n=436 
In-depth 
interview 
(IDI), n=12 
Ageb       
18-25 5 76 1 
26-35 5 85 5 
36-45 5 62 2 
46-55 4 119 1 
56-65 3 94 3 
Sex 
   
Female 13 221 10 
Male 15 215 2 
Site 
   
Urban  10 215 6 
Rural 18 221 6 
Area 
   
Urban middle-income 5 102 5 
Urban low-resource 5 113 1 
Rural more accessible 6 113 6 
Rural less accessible 12 108 0 
 
a
 Five focus groups were conducted, each with 5-6 participants. Two focus groups were conducted 
with women, two with men and one with both men and women. 
b
 Specific ages for one focus group with 6 participants at the rural site were not collected. Hence, the 
total number of participants categorized by age for the focus groups does not add up to 28. 
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Table 2. Awareness, health care provider recommendation and use of pandemic influenza 
vaccines 
  
Overall 
(%)  Age group (%)
a
 Area of residence (%) Sex (%) 
  
  
Youn
ger 
Old
er 
P 
valu
eb 
Urba
n 
midd
le-
inco
me  
Urba
n 
low-
resou
rce 
Rural 
more 
accessi
ble 
Rural 
less 
accessi
ble 
P 
valu
eb 
Fem
ale 
Ma
le 
P 
valu
eb 
  n = 436 
n = 
223 
n = 
213   
n = 
102 
n = 
113 
n = 
113 
n = 
108   
n = 
221 
n = 
21
5   
Awareness of vaccines to 
prevent swine flu 
          
 
Nasal vaccinec 26.6 31.4 
21.
6 * 47.1 25.7 26.6 8.3 *** 25.8 
27.
4  
Injectable vaccined 23.4 26.0 
20.
7 
 
28.4 26.6 17.7 21.3 
 
21.7 
25.
1  
Recommendation by health 
care provider  
          
 
To take a swine flu 
vaccinee 15.8 20.6 
10.
8 ** 23.5 20.4 13.3 6.5 ** 13.1 
18.
6  
Uptake of swine flu 
vaccine 
           
 
Personal usef 8.3 9.4 7.0 
 
13.7 6.2 9.7 3.7 * 5.9 
10.
7  
Others in 
householdg 10.6 NA NA   19.6 7.1 14.2 1.9 *** NA NA  
 
a
 Younger age group: 18-45 years, Older age group: 46-65 years; NA: Not applicable 
b
 Fisher‟s exact test was used to compare proportions across age groups, area of residence and sex: 
*p≤0.05, **p≤0.01, ***p≤0.001 
e 
Frequency of affirmative responses to the question: “Has your health care provider ever 
recommended your taking a vaccine to protect against swine flu?” 
f 
Frequency of affirmative responses to the question: “Have you ever taken a vaccine to prevent swine 
flu?” 
g 
Frequency of affirmative responses to the question: “Has anyone else in your household ever taken 
a vaccine to prevent swine flu?” 
All questions were enquired in the local language, Marathi, and translations have been provided here. 
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Table 3. Reasons for non-use of pandemic influenza vaccines 
Reasons for not 
taking the 
pandemic 
influenza 
vaccine 
(personally or 
for someone in 
the household)
a
 
Overal
l (%) Area of residence (%) Sex (%) 
 
Urban 
middle-
income 
Urban 
low-
resourc
e 
Rural 
more 
accessible 
Rural less 
accessible 
P 
value
b
 Female Male 
P 
value
b
 
n = 436 n = 102 n = 113 n = 113 n = 108   n = 221 
n = 
215   
Low risk attributed 
to influenza  55.0 46.1 57.5 60.2 55.6 
 
49.8 60.5 * 
Sufficient 
precautionary 
measures already 
taken 15.8 29.4 25.7 6.2 2.8 *** 15.8 15.8  
Access (where and 
how to get it) 14.7 7.8 9.7 17.7 23.1 ** 11.8 17.7  
Unaware of 
vaccine  11.7 2.0 13.3 12.4 18.5 *** 12.7 10.7  
Cost of vaccine 5.0 4.9 8.0 3.5 3.7  5.9 4.2  
 
a
 Response to the question: “For you or anyone in your household who did not take the vaccine for 
swine flu, were there any particular reasons not to take it? Can you explain why some (or all) did not 
take it?” were coded into categories described in the table. Multiple categories could have been 
mentioned and coded for each respondent. 7.3% of respondents did not provide a reason. Categories 
reported by less than 5% are not presented. They included: lack of encouragement by health care 
provider (3.9%), other miscellaneous (3.4%), vaccine shortage due to high demand (2.1%), no time to 
take the vaccine (1.6%), doubts about vaccine effectiveness (0.9%), and general avoidance of 
medication (0.9%). 
b
 Fisher‟s exact test was used to compare proportions across area of residence and sex: *p≤0.05, 
**p≤0.01, ***p≤0.001. No differences were observed across age groups and they have hence not 
been presented. 
D
ow
nl
oa
de
d 
by
 [H
arv
ard
 L
ibr
ary
], 
[M
itc
he
ll G
. W
eis
s] 
at 
15
:42
 25
 Ju
ne
 20
15
 
 25 
 
Table 4. Preference for injectable or nasal pandemic influenza vaccine  
  Overall Age group   Area of residence   Sex   
  
  
Young
er 
Old
er 
p 
valu
e
a
 
Urba
n-
middl
e 
inco
me  
Urban 
low-
resour
ce 
Rural 
more 
accessi
ble 
Rural 
less 
accessi
ble 
p 
valu
e
a
 
Fema
le 
Mal
e 
p 
valu
e
a 
  n = 436 
n = 
223 
n = 
213   
n = 
102 
n = 
113 n = 113 n = 108   
n = 
221 
n = 
215   
More powerful 
vaccine (%)
b
 
          
  
Neither  0.0 0.0 0.0 
 
0.0 0.0 0.0 0.0 
 
0.0 0.0   
Both equal  3.0 2.7 3.3 
 
2.9 3.5 1.8 3.7 
 
3.6 2.3   
Injection  44.3 44.4 44.1 
 
42.2 51.3 40.7 42.6 
 
45.2 
43.
3   
Nasal spray  32.6 36.3 28.6 
 
33.3 31.0 37.2 28.7 
 
26.2 
39.
1 ** 
Cannot say  20.2 16.6 23.9 
 
21.6 14.2 20.4 25.0 
 
24.9 
15.
3 * 
Safer vaccine (%)c 
          
  
Neither  0.7 0.5 0.9 
 
0.0 0.9 0.0 1.9 
 
0.9 0.5   
Both equal  9.6 11.7 7.5 
 
9.8 5.3 14.2 9.3 
 
12.2 7.0   
Injection  57.1 54.7 59.6 
 
46.1 64.6 54.9 62.0 * 55.2 
59.
1   
Nasal spray  27.5 29.6 25.4 
 
42.2 24.8 25.7 18.5 ** 25.8 
29.
3   
Cannot say  5.0 3.6 6.6 
 
2.0 4.4 5.3 8.3 
 
5.9 4.2   
Personal preference 
(%)d 
          
  
No 
preference  11.2 8.1 14.6 * 9.8 6.2 10.6 18.5 * 12.7 9.8   
Injection  58.5 59.2 57.8 
 
52.9 65.5 54.9 60.2 
 
59.3 
57.
7   
Nasal spray  30.3 32.7 27.7 
 
37.3 34.5 28.3 21.3   28.1 
32.
6   
 
a
 Fisher‟s exact test was used to compare proportions across age groups, area of residence and sex, 
*p≤0.05, **p≤0.01, ***p≤0.001 
b
 Frequency of responses to the question: “Do you think either of these vaccines (the nasal spray or 
the injection) would be more powerful and better able to protect you against swine flu? … Why?” 
c
 Frequency of responses to the question: “Which one of these vaccines (nasal spray or injection) do 
you think would be safer for you? … Why?” 
d
 Frequency of responses to the question: “If you could choose either of these vaccines to protect 
yourself against swine flu, which one would you prefer, the nasal spray or the injection? … Why?” 
All questions were enquired in the local language, Marathi, and translations have been provided here. 
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Table 5. Reasons for preferring an injectable vaccine or a nasal vaccine for pandemic influenza 
A) Reasons for preferring an injectable vaccine 
Theme Illustrative quote 
Perceived powerfulness of vaccine 
Injectable vaccine spreads through the 
body from absorption in the blood 
“In our village it is believed that the medicine reaches the whole body only 
through an injection” (29 yr, rural woman) 
Injectable vaccine spreads faster in 
the body 
“An injectable vaccine spreads all over quickly. The nasal one takes time while 
the injection spreads faster” (23 yr, urban man) 
Injectable vaccine has longer lasting 
effects 
“Injectable vaccine because its effect will last for long” (31 yr, rural man) 
Nasal vaccine may be expelled while 
breathing, sneezing or in mucus 
“The injectable vaccine allows the medicine to disperse internally. The 
medicine if administered through the nasal route will get expelled through 
breath. It won’t go inside” (64 yr, rural man) 
Nasal vaccine may not reach all parts 
of the body 
“Injectable vaccine is better because the nasal vaccine will travel with the 
breath and only reach the lungs while the injectable one will circulate through 
the blood in the entire body” (60 yr, rural man) 
Pain caused by injectable vaccine is an 
indication of its powerfulness 
“Actually, pain at the injection site is considered as good sign” (rural woman, 
FGD) 
Side effects or safety concerns of alternative 
Fear of numerous side effects from 
nasal vaccine 
“If given in the nose then it creates irritation in the throat, and the whole 
mouth becomes bitter” (46 yr, rural woman) 
Familiarity and trust 
Past experience and familiarity with 
injections 
“I will prefer the injectable vaccine since we are used to taking injections. We 
have never taken it through the nose” (27 yr, urban man) 
Implicit trust in injections “Injection- all I can understand is that, it will be effective when we take it” (50 
yr, woman) 
Fear of relatively unknown nasal 
vaccine 
“A person fears taking it through the nose. There is no fear in an injection. I 
fear the nasal one” (48 yr, rural woman) 
 
B) Reasons for preferring a nasal vaccine 
Theme Illustrative quote 
Perceived powerfulness of vaccine 
Nasal vaccine can reach all parts of the 
body through breath 
“[I prefer] nasal as when we breathe it reaches the whole body. Injection does 
not affect the body so fast” (59 years, urban woman) 
Nasal vaccine has a more immediate 
effect 
“Will take it through the nose. It will have an immediate effect” (50 yr, rural 
woman) 
Nasal vaccine is administered through 
the nose where germs enter 
“Nasal [is preferred] because we would have the disease through there…Its 
effect would be more than injectable” (21 yr, rural man) 
Nasal vaccine has desirable side 
effects indicative of vaccine doing its 
job 
“Nasal administration must cause tingling and stinging….You don’t feel 
anything after taking the injectable vaccine but you can feel the medicine 
going inside and also the stinging caused when administered through the 
nose” (47 yr, rural man) 
Side effects or safety concerns of alternative 
Fear of needles or pain caused by 
injectable vaccines  
“The nasal one is better. With an injection, there is inflammation or pain 
later” (57 yr, urban man) 
Concerns regarding potential re-use of 
needles in injectable vaccines 
“There is a risk associated with the injection because an already used syringe 
may be used again, unlike in case of a nasal vaccine which I think spreads in 
the entire body in the vapour form” (65 yr, urban man) 
Table 5(A) lists main themes and illustrative quotes distilled from respondent narratives regarding why an injectable 
vaccine was preferred over a nasal one. Narratives from focus group discussions and open questions in semi-structured 
interviews were analysed thematically grouped under broad domains of perceived powerfulness (or efficacy), side effects 
or safety concerns and familiarity, trust. Explanations provided were either perceived advantages of the injectable vaccine 
(text in black) or perceived disadvantages of the nasal vaccine (text in red). Similarly, in Table 5(B), explanations for 
preference of the nasal vaccine were due to either perceived benefits of the nasal vaccine (text in black) or perceived 
disadvantages of the injectable vaccine (text in red). 
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